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ABSTRACT
Recently, in the field of asthma, there has been a substantial number of clinical trials which include health-
related quality of life (HRQoL) as one of the outcomes. These studies employ two types of instruments for as-
sessing HRQoL, generic and disease-specific instruments each being used individually or in combination．
It has been proposed that treatments for patients aimed at increasing longevity, prevention of future morbidity,
or making patients feel better. To achieve the last purpose, it is considered that HRQoL should be evaluated.
Moreover, there are several reports demonstrating only weak to moderate correlations between physiological
variables and HRQoL in patients with asthma. This is another reason for the importance of direct evaluation of
HRQoL in conjunction with the conventional clinical indices.
Pharmacological interventions based on guidelines seem to improve not only pulmonary function but also
HRQoL in patients with asthma. However, all managements do not necessarily improve HRQoL, therefore as-
sessing HRQoL is strongly recommended in clinical trials.
However, the benefit of including HRQoL in evaluation of patients management is still unknown. It is valid that
evaluation of HRQoL in clinical practice can both reveal patients problems that were not spontaneously identi-
fied by patients themselves and allow physicians focus on specific problems. Until such data are available, the
benefit of assessing HRQoL in clinical practice will remain uncertain.
Although conducting more clinical trials that prove efficacy in clinical practice is required, consideration of
HRQoL in patients has recently been recognized as an important topic in the asthma field. It can be said that
outcomes in health care for asthma will shift from the physiological aspect to humanistic aspect.
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INTRODUCTION
Health-related quality of life (HRQoL), in other words
health status, is become an emerging concept in this
decade . 1 Various questionnaires have been devel-
oped in many areas to evaluate HRQoL, especially in
chronic diseases. However, measuring HRQoL is not
prevalent in most interventional clinical research and
clinical practice, especially not in Japan. In this re-
spect, the concept of measuring HRQoL in asthma
seems to be leading the field. Recently, many clinical
researchers and general practitioners are recognizing
the importance of HRQoL as an outcome of evaluat-
ing asthma. In this review article, the basic concept of
HRQoL, a variety of measurement instruments, the
characteristics of HRQoL in adult patients with
asthma, reported impacts of treatments of asthma on
HRQoL, and estimated future direction of measuring
HRQoL in asthma will be discussed.
THE CONCEPT OF HEALTH-RELATED
QUALITY OF LIFE
Quality of life involves all valued aspects of life. There
are several perspectives of life that are not generally
considered as directly related to health, including in-
come, freedom, and quality of the environment. Al-
though they may affect health, these aspects are usu-
ally distant from health or medical concerns . The
HRQoL is the concept of quality of life , which in-
cludes aspects of life directly associated with health.
HRQoL usually includes symptoms , moods , func-
tional activities, however, it excludes such variables
as income, freedom, and environment.1 When treat-
ing patients, clinicians focus on HRQoL, although al-
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Table 1 Examples of generic and asthma specific instruments for health-related quality of life
Asthma specific instrumentsGeneric instruments
Asthma Quality of Life Questionnaire (AQLQ)6,7Sickness Impact Profile (SIP)3
Living with Asthma Questionnaire (LWAQ)8Short-form 36 (SF-36)4
St. George’ sRespiratory Questionnaire (SGRQ)9EuroQOL5
Airways Questionnaire 20 (AQ20)10
most all aspects of life can be health related. HRQoL,
health status, and functional status are often used in-
terchangeably to refer to similar concepts.
It has been proposed that treatments for patients
are offered for the purpose of increasing longevity, of-
fering prevention of morbidity, or simply for making
patients feel better. Although the first two of these
three endpoints are relatively easy to measure, the
last one is somewhat difficult. Therefore , clinicians
have been substituting physiological variables for
measuring the third. However, the importance of di-
rect measurement of patients’ feelings directly re-
lated to health has been noted recently, so the con-
cept of HRQoL was developed.2
Measuring HRQoL is important in chronic diseases
because physiological variables, such as those from
laboratory tests and pulmonary function tests, usually
have poor correlations with functional capacity and
well-being, the areas in which patients are most inter-
ested.1 Another reason for the importance of measur-
ing HRQoL is the commonly observed phenomena
that two patients with the same clinical and physi-
ological variables often have different responses. For
example, some patients may continue to work with-
out major depression, others may quit their jobs and
develop depressive symptoms.1
VARIETY OF MEASUREMENT INSTRU-
MENTS
HRQoL is usually evaluated using several measure-
ment instruments . More common instruments are
questionnaires consisting of multiple items or ques-
tions . There are some instruments that evaluate
HRQoL using a global scale and there are others us-
ing a visual analogue scale . There are also several
modes of administration of the instruments such as
interviews, telephone calls, self-interviews, and surro-
gate responders.1 However, the most important thing
when evaluating HRQoL for patients is to use instru-
ments that are proven to be valid, reliable, and re-
sponsive.1 The use of an instrument which does not
have proven validity should be avoided.
There are two major types of instruments used to
evaluate HRQoL in chronic diseases, generic and dis-
ease specific instruments (Table 1). Generic instru-
ments attempt to measure all the important aspects of
HRQoL. The advantages of generic instruments in-
cludes the capacity to evaluate a variety of diseases
and the flexibility be used in any population. Further-
more , comparisons of HRQoL in many underlying
conditions can be made. However, unresponsiveness
to changes in specific condition is a disadvantage .
The second type of instrument is the disease specific
instrument. This instrument involves only important
aspects of HRQoL in specific diseases. The advantage
of using specific instruments is superiority in respon-
siveness and discriminating ability．
Recently, HRQoL measures have been frequently
chosen as primary and secondary outcomes in clini-
cal trials. Generic and specific instruments are used
individually and in combination. Treatments that are
effective for physiological variables and mortality do
not necessarily have beneficial effects on HRQoL ,
however evaluation of HRQoL in clinical trial is con-
sidered to be important.
CHARACTERISTICS OF HRQOL IN ADULT
PATIENTS WITH ASTHMA
Patients with asthma are bothered by the symptoms
themselves, such as shortness of breath, chest tight-
ness, wheeze, and cough, and clinicians usually focus
on these asthma symptoms. However , in addition ,
many patients have problems other than asthma
symptoms, including disability in physical and daily
activities, handicaps in work, and mental problems.
Therefore, HRQoL must be measured with conven-
tional indices to obtain a complete picture of a pa-
tient’s health.11
There have been some reports that revealed the
characteristics of HRQoL in asthma . 6-8,10,12-14 Only
weak to moderate correlation between clinical physi-
ological measures and HRQoL were demon-
strated.15,16 This is one of the reasons for importance
of obtaining HRQoL for patients in conjunction with
the conventional clinical indices . However , correla-
tion between changes in physiological measures and
changes in HRQoL scores assessed with the Asthma
Quality of Life Questionnaire (AQLQ) are reportedly
somewhat stronger . 6-17 Therefore , HRQoL may re-
flect changes in asthma control more than physi-
ologic measures at one point . Although correlation
between physiologic measures and HRQoL are weak
to moderate, controlling peak expiratory flow (PEF)
over 80% of predicted value is significantly associated
with better HRQoL.18
As for symptoms, there have been several studies
demonstrating relationships with HRQoL. Relatively
strong relationships were found between overall and
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symptom score for the AQLQ and both morning and
daytime symptoms, however, there were only moder-
ate relationships between scores for other domains
and morning and daytime symptom score . 17 In an
analysis using a generic instrument, the Sickness Im-
pact Profile (SIP) , significant correlations between
nighttime and daytime symptoms and overall HRQoL
score, as well as limited but significant association be-
tween those symptoms and scores for all other do-
mains were observed . 19 Although both HRQoL
scores assessed with generic and disease-specific in-
struments were significantly influenced by symp-
toms, the latter is reported to be better for discrimi-
nating patients with asthma.20 In addition to symp-
toms, a number of aggregate measures have been
used to define severity in patients with asthma. An in-
verse relationship has been found between HRQoL
and severity using these aggregate indicators .6,16,21
Aggregate scales seems to be more accurate predic-
tors for HRQoL than single indicators of severity in
patients with asthma. Strong relationships have been
found between aggregate severity scales and score
for specific instruments.6,16 Symptoms evaluated with
visual analogue scale (VAS) have been reported to be
strongly correlated with HRQoL assessed with the
AQLQ.22 In another report, a significant correlation
was found between the number of problems associ-
ated with asthma control and HRQoL assessed with
the short-form 36 (SF-36) , the AQLQ, and the St .
George’s Respiratory Questionnaire (SGRQ).23
It has been reported that clinical predictors of
HRQoL for patients with asthma depend on the sever-
ity of the disease. Although intensity of shortness of
breath and rescue β2-agonist use are reportedly inde-
pendent predictors of HRQoL for patients with mild
asthma, only intensity of shortness of breath inde-
pendently predicts HRQoL for moderate to severe
asthma.24
Although several factors can influence HRQoL for
patients with asthma,25 there have been inconsistent
reports about age. It is true that HRQoL is also im-
paired in elderly patients, 26 however , some studies
demonstrated that older adults have poorer
HRQoL,27-29 and others indicated that they are less
distressed by their asthma than are younger
adults.12,29 In terms of gender, although several stud-
ies reported no gender difference in HRQoL in pa-
tients with asthma,25,28,30 others have demonstrated
significant gender effects.12,13,16,21,27,31 According to
those reports, men with asthma generally have sig-
nificantly better HRQoL. There are also some reports
that revealed a correlation between higher education
and better HRQoL for patients with asthma.16
In comparison of generic and disease-specific
HRQoL instruments , it is reported that scores as-
sessed with the SF-36 and the AQLQ were highly cor-
related, and that both instruments had strong dis-
criminative properties and were able to characterize
patients with moderate asthma.32 Other reports re-
vealed that the changes in the scores assessed with
the SGRQ, a disease-specific instrument, are slightly
better than those assessed with the 15D, a generic in-
strument, with the changes in clinical variables.33 In
comparing the two disease-specific instruments, the
SGRQ and the AQLQ, each measure is comparable to
another, with the exception of the SGRQ symptoms
score which shows less responsiveness.34 The AQLQ
is also reported to be more responsive than the Liv-
ing with Asthma Questionnaire (LWAQ) and Airways
Questionnaire 20 (AQ20).35
IMPACTS OF TREATMENTS FOR ASTHMA
ON HRQOL
When considering treatment effects on HRQoL, there
are two methods to test the effects. One is an evalu-
ation observing statistically significant improvements
in comparison to placebo or baseline values. Another
is a minimal clinically important difference (MCID),
which is the minimal difference patients perceive as
meaningful. For example, a MCID on the AQLQ is
determined as 0.5 and that on the SGRQ is 4.6,36 Sta-
tistically significant change in HRQoL is not necessar-
ily a clinically meaningful change. Therefore, presen-
tation of clinical trial results in this manner is more
meaningful and easier to interpret.
When evaluating treatment effects on HRQoL, dif-
ference of instruments used should be considered.
Generic instruments tend to be less sensitive than
disease-specific instruments. Disease-specific instru-
ments, heavily weighed in the symptom domain of
HRQoL, will be more sensitive to interventions tar-
geted on symptom improvement.37 Therefore, physi-
cians should be aware of the characteristics of the in-
struments used.
There have been sizable reports that evaluate the
treatment effects on HRQoL in patients with asthma.
It is reasonable to expect that treatments effective for
symptoms and pulmonary function will also produce
improvements in HRQoL. Inhaled corticosteroid
(ICS) plays a key role in the treatment of patients
with asthma. ICSs including budesonide, fluticasone,
and beclomethasone generally control asthma and
improve HRQoL in many clinical studies.38-44 Long-
acting β2-agonists (LABA) including salmeterol and
formoterol also improve HRQoL in patients with
asthma when added to baseline use of inhaled corti-
costeroids . 17,45-50 ICSLABA such as fluticasone
propionatesalmeterol combination is also reported
to be effective for improvement of HRQoL . 51
Leukotriene-receptor antagonist , such as montelu-
kast, zafirlukast, and zileuton, have favorable effects
on HRQoL.52-58 The difference in HRQoL between pa-
tients who use β2-agonists on a PRN basis and pa-
tients who use it regularly is not inconsistent . 59,60
Some other pharmacological interventions, such as
nedocrimil sodium61 and omalizumab, an anti-IgE an-
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tibody,62,63 were also proven to improve HRQoL in pa-
tients with asthma. Patch formulation of tulobuterol
recently available in Japan, which releases its active
ingredients in a sustained fashion , 64 can improve
HRQoL in patients with asthma, however , there is
still no direct evidence. In general, guideline-based
asthma treatments improve HRQoL.65 However, phy-
sicians must be aware that most medications can im-
prove physiological variables such as pulmonary
function, but sometimes they can worsen HRQoL.
These kind of adverse effects on HRQoL are reported
in patients with chronic obstructive pulmonary dis-
ease.66
In terms of education, reported results are incon-
sistent.67-69 Some reports showed efficacy in patients
with moderate-to-severe asthma.68,69 Pharmacist ad-
vise is also effective for improving HRQoL in patients
with asthma.70 However, in these new fields, some
further studies are needed to confirm these effects.
FUTURE DIRECTION OF MEASURING
HRQOL IN ASTHMA
Substantial numbers of clinical trials that include
HRQoL as one of the outcomes have been reported in
this decade. However, whether including evaluation
of HRQoL benefits patients management is still un-
known. It is valid that evaluation of HRQoL in clinical
practice can reveal patients’ problems that are not
spontaneously identified by patients and let physi-
cians more closely focus on problems. It is interest-
ing to compare HRQoL-based treatment with
guideline-based treatment for testing the efficacy of
evaluating HRQoL in patients with asthma. Until such
data are available, the benefit of using these HRQoL
questionnaires in clinical practice is uncertain．
Predicting value of HRQoL in patients with asthma
is another issue. Although self-reported lifestyle re-
striction from asthma can predict the frequency of
visiting the emergency room , 71 it is unknown
whether HRQoL predicts the frequency of emer-
gency room visits and admissions . Furthermore ,
changes in HRQoL during longer periods should be
investigated . Recently , an instrument to evaluate
HRQoL during an acute asthma exacerbation was de-
veloped . 72 Elucidating meaning and benefits of as-
sessing HRQoL in the acute phase is a new issue.
Although conducting clinical trials that demon-
strate their efficacy in clinical practice is required ,
consideration of patients’ HRQoL has been recog-
nized as more important in the asthma field. It can be
said that outcomes in health care for asthma are shift-
ing from the physiological aspect to the humanistic
aspect.73
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